HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A peripheral signature of Alzheimer's disease featuring microbiota-gut-brain axis markers.

AbstractBACKGROUND:
Increasing evidence links the gut microbiota (GM) to Alzheimer's disease (AD) but the mechanisms through which gut bacteria influence the brain are still unclear. This study tests the hypothesis that GM and mediators of the microbiota-gut-brain axis (MGBA) are associated with the amyloid cascade in sporadic AD.
METHODS:
We included 34 patients with cognitive impairment due to AD (CI-AD), 37 patients with cognitive impairment not due to AD (CI-NAD), and 13 cognitively unimpaired persons (CU). We studied the following systems: (1) fecal GM, with 16S rRNA sequencing; (2) a panel of putative MGBA mediators in the blood including immune and endothelial markers as bacterial products (i.e., lipopolysaccharide, LPS), cell adhesion molecules (CAMs) indicative of endothelial dysfunction (VCAM-1, PECAM-1), vascular changes (P-, E-Selectin), and upregulated after infections (NCAM, ICAM-1), as well as pro- (IL1β, IL6, TNFα, IL18) and anti- (IL10) inflammatory cytokines; (3) the amyloid cascade with amyloid PET, plasma phosphorylated tau (pTau-181, for tau pathology), neurofilament light chain (NfL, for neurodegeneration), and global cognition measured using MMSE and ADAScog. We performed 3-group comparisons of markers in the 3 systems and calculated correlation matrices for the pooled group of CI-AD and CU as well as CI-NAD and CU. Patterns of associations based on Spearman's rho were used to validate the study hypothesis.
RESULTS:
CI-AD were characterized by (1) higher abundance of Clostridia_UCG-014 and decreased abundance of Moryella and Blautia (p < .04); (2) elevated levels of LPS (p < .03), upregulation of CAMs, Il1β, IL6, and TNFα, and downregulation of IL10 (p < .05); (3) increased brain amyloid, plasma pTau-181, and NfL (p < 0.004) compared with the other groups. CI-NAD showed (1) higher abundance of [Eubacterium] coprostanoligenes group and Collinsella and decreased abundance of Lachnospiraceae_ND3007_group, [Ruminococcus]_gnavus_group and Oscillibacter (p < .03); (2) upregulation of PECAM-1 and TNFα (p < .03); (4) increased plasma levels of NfL (p < .02) compared with CU. Different GM genera were associated with immune and endothelial markers in both CI-NAD and CI-AD but these mediators were widely related to amyloid cascade markers only in CI-AD.
CONCLUSIONS:
Specific bacterial genera are associated with immune and endothelial MGBA mediators, and these are associated with amyloid cascade markers in sporadic AD. The physiological mechanisms linking the GM to the amyloid cascade should be further investigated to elucidate their potential therapeutic implications.
AuthorsMoira Marizzoni, Peppino Mirabelli, Elisa Mombelli, Luigi Coppola, Cristina Festari, Nicola Lopizzo, Delia Luongo, Monica Mazzelli, Daniele Naviglio, Jean-Louis Blouin, Marc Abramowicz, Marco Salvatore, Michela Pievani, Annamaria Cattaneo, Giovanni B Frisoni
JournalAlzheimer's research & therapy (Alzheimers Res Ther) Vol. 15 Issue 1 Pg. 101 (05 31 2023) ISSN: 1758-9193 [Electronic] England
PMID37254223 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2023. The Author(s).
Chemical References
  • Tumor Necrosis Factor-alpha
  • Lipopolysaccharides
  • Platelet Endothelial Cell Adhesion Molecule-1
  • RNA, Ribosomal, 16S
  • methylglyoxal bis(3-aminopropylamidinohydrazone)
  • Interleukin-10
  • Interleukin-6
  • NAD
  • Biomarkers
  • Amyloid beta-Peptides
Topics
  • Humans
  • Alzheimer Disease (metabolism)
  • Tumor Necrosis Factor-alpha
  • Brain-Gut Axis
  • Lipopolysaccharides
  • Platelet Endothelial Cell Adhesion Molecule-1
  • RNA, Ribosomal, 16S
  • Interleukin-10
  • Interleukin-6
  • NAD
  • Biomarkers
  • Amyloid beta-Peptides

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: